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Possible role of anti-TNF monoclonal antibodies in
the treatment of Mycobacterium marinum infection
SIR, TNF plays a major role in mycobacterial defence.
Mycobacterium marinum (M. marinum) infection typically
presents with chronic inflammation of hands and feet
[1, 2]. Its diagnosis is often delayed and antibiotic treat-
ment is long-standing. Safe re-exposition to anti-TNF
therapy after successful bacterial elimination was
reported [3], yet addition of anti-TNF monoclonal anti-
bodies to control inflammation seemed paradoxical so far.
A 44-year-old Caucasian farmer presented with dacty-
litis of a toe. Local glucocorticoid injection induced a
chronic fistula, which was surgically removed. Several
months later carpal arthritis and tenosynovitis developed
and the patient reported inflammatory back pain.
Suspecting spondyloarthritis, NSAIDs and glucocorticoids
were introduced, later co-medicated with MTX, yet proved
insufficient. Assessment of latent tuberculosis before
anti-TNF therapy showed a positive IFN-g-release assay
[IGRA; QuantiFERON-TB Gold in Tube (QFT), Cellestis
Ltd, Victoria, Australia; Fig. 1a] [4]. Isoniazid was intro-
duced against latent tuberculosis. Etanercept was
added 1 month later and within few weeks synovitis and
back pain improved. Unexpectedly carpal tenosynovitis
FIG. 1 (a) Laboratory findings regarding M. marinum in-
fection. np: not performed; in: PCR reaction inhibited; INH:
isoniazid; R: rifampin; E: ethambutol; C: clarithromycin.
(b) Histological findings of synovial tissue. Synovial tissue
specimens of the carpus showing classical findings of
M. marinum infection: granuloma formation, dense
infiltrates of mononuclear cells and several giant cells
(arrow).
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deteriorated. Synovial biopsy revealed granuloma forma-
tion with giant cells (Fig. 1b). Microbiological cultures were
not performed and PCR for mycobacteria failed due to
reaction inhibition (Fig. 1a). MTX was stopped due to ele-
vated liver enzymes. Synovitis flared and the fistula of the
toe reopened. A second synovial biopsy led to the detec-
tion of M. marinum and to the discontinuation of etaner-
cept. Histology was unchanged. Given the high-grade
infection in an immunocompromized patient, standard
therapy with ethambutol, clarithromycin and rifampin
was initiated and after 4 months clarythromycin was
stopped [2]. Yet carpal synovitis progressed. MRI
showed synovial proliferation with bone oedema without
destructive osteomyelitis. After thorough discussion and
with informed consent of the patient, we added a treat-
ment with the monoclonal TNF antibody infliximab at a
dosage of 5 mg/kg/month. Hereby, clinical remission
was induced. After stopping anti-bacterial therapy, a
third synovial biopsy of the carpus showed marked im-
provement of inflammation and part resolution of the
granuloma. There was no growth of mycobacteria, yet
PCR for M. marinum was positive. QFT was then negative.
Infliximab was stopped. Ten months later the patient had
no signs of cutaneous or soft tissue inflammation.
On-demand NSAIDs are sufficient to control intermittent
back pain.
The positive QFT was interpreted as latent tuberculosis
infection and treated accordingly. Yet, further work based
on relapse during etanercept and MTX revealed active M.
marinum infection in the cultured biopsy (Fig. 1a). QFT
measures IFN-g release by T lymphocytes in response
to specific antigens. Notably, few non-tuberculous myco-
bacteria like M. marinum, Mycobacterium kansasii and
Mycobacterium szulgai also express the antigens used
in the QFT [4, 5] explaining the positive IGRA.
The positive M. marinum-PCR in the third biopsy is not
surprising as it might equally detect dead and vital par-
ticles of bacterial DNA and is therefore not helpful in sur-
veillance [6]. Even more so as the initial PCR had failed.
Follow-up can only be properly managed by thorough
clinical controls, instruction of the patient and repeating
bacterial cultures.
As TNF is known to play a central role in granuloma
persistence, it might surprise that despite anti-TNF treat-
ment with etanercept, the pathologist reported classical
findings of M. marinum infection such as granuloma for-
mation and giant cells (Fig. 1b). Current data show that
monoclonal antibodies to TNF, but not the soluble recep-
tor etanercept, are effective in treating granulomatous dis-
eases like Crohn’s disease, sarcoidosis or localized WG.
Thus, our histological data are in perfect agreement with
differential clinical effects of soluble receptors vs mono-
clonal antibodies.
Reactivation of latent Mycobacterium tuberculosis in-
fection caused by TNF-blocking therapy may be fatal.
Therefore, clinicians are often reluctant to re-expose pa-
tients to anti-cytokine therapy after successful antibiotic
treatment. However, recently a TNF-blocking strategy was
successful in controlling inflammation in a life-threatening
tuberculous paradoxical reaction [7]. The question was
raised whether anti-TNF strategies might be helpful in crit-
ical situations of tuberculous paradoxical reactions [8].
Regarding M. marinum, recent case reports document
M. marinum infection under TNF inhibition, but also safe
re-exposition to anti-TNF therapy after elimination of the
bacteria [3, 9, 10]. In our case, local and systemic in-
flammation persisted for months despite adequate
anti-microbial treatment. Based on the considerations
above, we decided to use the monoclonal antibody inflix-
imab with the intent to control clinical signs of inflamma-
tion and to destroy local granuloma. This procedure
proved to be successful and raises the provocative ques-
tion of whether continuation or introduction of TNF inhib-
ition by monoclonal antibodies should not be advocated in
cases of localized granulomatous infections with M. mar-
inum. It is tempting to speculate that time to elimination of
bacteria as well as time to remission of inflammation could
be considerably shortened.
Rheumatology key message
. Anti-TNF monoclonal antibodies may help to con-
trol inflammation caused by M. marinum infection.
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Reversible cerebral vasoconstriction syndrome in a
female patient with systemic lupus erythematosus
SIR, Headaches are common in patients with SLE, espe-
cially those suffering from CNS involvement (CNS-SLE)
with or without cerebral vasculitis [1, 2]. Reversible cere-
bral vasoconstriction syndrome (RCVS) is characterized
by the association of severe ‘thunderclap headaches’
with or without additional neurological manifestations
and a ‘string of beads’ appearance on cerebral arteries,
which resolves spontaneously in 1–3 months [3]. RCVS
and cerebral vasculitis have several overlapping features.
We report a case of RCVS in an SLE patient that was
misdiagnosed initially as lupus-associated cerebral
vasculitis. To our knowledge, this is the first case of
RCVS described in an SLE patient.
A 40-year-old female patient was diagnosed with SLE at
the age of 25 years. She presented at the age of 27 years
with a severe flare-up characterized by intra-alveolar
haemorrhage and CNS-SLE (headaches, psychosis and
seizure). She had no aPLs. Her follow-up was character-
ized by poor treatment adherence.
Since December 2008, she has been followed up in our
department for World Health Organization classes IV–V
lupus nephritis and treated according to the Euro-Lupus
regimen. While clinico-biological remission was noted,
she presented 2 days before the fifth cyclophosphamide
pulse with an acute severe headache that disappeared
spontaneously and the patient received the planned
500 mg i.v. cyclophosphamide. Her treatment included
prednisone (30 mg/day), atorvastatin, omeprazole, calcium
carbonate and cholecalciferol.
She was readmitted to the hospital 2 days later for
acute severe headache associated with nausea and
vomiting. The headache was of sudden onset, recurrent,
described as ‘thunderclap headache’, peaking in <10 s
with maximal pain intensity graded as 9.5/10 on the
visual scale. She also experienced a brief generalized
seizure. Physical examination was normal. A head CT
scan was normal. The cerebrospinal fluid was haematic.
A cerebral magnetic resonance angiogram (MRA) demon-
strated multifocal cerebral arterial stenosis (Fig. 1A). The
diagnosis of lupus-associated cerebral vasculitis was
considered; she was treated promptly with three daily
pulses of 750 mg i.v. methylprednisolone, plasmapheresis
and levetiracetam.
The headaches persisted leading us to reconsider the
diagnosis. A careful awareness of the characteristics of
headaches and the neuro-angiographic findings led us
to advocate the hypothesis of RCVS; cyclophosphamide
was suspected to contribute to the cerebral
vasoconstriction.
We then changed our strategy: i.v. nimodipine, discon-
tinuation of plasmapheresis and replacement of cyclo-
phosphamide by mycophenolate mofetil (3 g/day). The
FIG. 1 Cerebral MRA findings. MRA showing multifocal segmental stenosis of cerebral arteries (A). Control MRA done
40 days later showing resolution of the cerebral arterial vasoconstriction (B). Arrows refer to the multifocal arterial
stenoses (A) that have almost completely regressed (B).
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